What is Enliven Therapeutics Cash-to-Debt?
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Enliven Therapeutics's cash to debt ratio for the quarter that ended in Mar. 2024 was 1,271.84.
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Enliven Therapeutics could pay off its debt using the cash in hand for the quarter that ended in Mar. 2024.
The historical rank and industry rank for Enliven Therapeutics's Cash-to-Debt or its related term are showing as below:
ELVN'
s Cash-to-Debt Range Over the Past 10 Years
Min: 233.86 Med: 793.61 Max: 1271.84
Current: 1271.84
During the past 4 years, Enliven Therapeutics's highest Cash to Debt Ratio was 1271.84. The lowest was 233.86. And the median was 793.61.
Enliven Therapeutics Cash-to-Debt Historical Data
The historical data trend for Enliven Therapeutics's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
Enliven Therapeutics Cash-to-Debt Chart
|
Enliven Therapeutics Annual Data
|
|
Trend |
Dec20 |
Dec21 |
Dec22 |
Dec23 |
| Cash-to-Debt |
|
1,241.57 |
691.98 |
233.86 |
755.67 |
|
Enliven Therapeutics Quarterly Data
|
|
Dec20 |
Sep21 |
Dec21 |
Mar22 |
Jun22 |
Sep22 |
Dec22 |
Mar23 |
Jun23 |
Sep23 |
Dec23 |
Mar24 |
| Cash-to-Debt |
Get a 7-Day Free Trial
|
|
|
|
|
896.02 |
844.57 |
793.61 |
755.67 |
1,271.84 |
Competitive Comparison of Enliven Therapeutics's Cash-to-Debt
For the Biotechnology subindustry, Enliven Therapeutics's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Enliven Therapeutics's Cash-to-Debt Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Enliven Therapeutics's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Enliven Therapeutics's Cash-to-Debt falls into.
Enliven Therapeutics Cash-to-Debt Calculation
This is the ratio of a company's
Cash, Cash Equivalents, Marketable Securities
to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.
Enliven Therapeutics's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:
Enliven Therapeutics's Cash to Debt Ratio for the quarter that ended in Mar. 2024 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enliven Therapeutics (Enliven Therapeutics) Business Description
Traded in Other Exchanges
N/A
Address
6200 Lookout Road, Boulder, CO, USA, 80301
Enliven Therapeutics Inc is a clinical-stage precision oncology company focused on the discovery and development of potentially best-in-class or first-in-class precision oncology therapies. Enliven's programs are designed to address issues such as tolerability, combinability, resistance and disease escape through brain metastases.
Executives
| Anish Patel |
officer: Chief Operating Officer |
C/O ENLIVEN THERAPEUTICS INC, 6200 LOOKOUT ROAD, BOULDER CO 80301 |
| Benjamin Hohl |
officer: Chief Financial Officer |
6200 LOOKOUT ROAD, BOULDER CO 80301 |
| Joseph P Lyssikatos |
director, officer: Chief Scientific Officer |
6200 LOOKOUT ROAD, BOULDER CO 80301 |
| Samuel Kintz |
director, officer: President and CEO |
ENLIVEN THERAPEUTICS INC, 6200 LOOKOUT ROAD, BOULDER CO 80301 |
| Richard A. Heyman |
director |
5871 OBERLIN DRIVE, SUITE 150, SAN DIEGO CA 92121 |
| 5am Partners Vi, Llc |
10 percent owner |
501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107 |
| Rishi Gupta |
director, 10 percent owner |
C/O CHEMOCENTRYX, INC., 850 MAUDE AVENUE, MOUNTAIN VIEW CA 94043 |
| Andrew J. Schwab |
director |
C/O 5AM VENTURES, 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107 |
| Helen Louise Collins |
director |
TWO CORPORATE DRIVE, SOUTH SAN FRANCISCO CA 94080 |
| Jake Bauer |
director |
C/O MYOKARDIA, INC., 333 ALLERTON AVENUE, SOUTH SAN FRANCISCO CA 94080 |
| 5am Opportunities I, L.p. |
10 percent owner |
501 SECOND STREET, SUITE 350, SAN FRANCISCO CA 94107 |
| 5am Opportunities I (gp), Llc |
10 percent owner |
501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107 |
| Orbimed Genesis Gp Llc |
10 percent owner |
601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022 |
| Kush Parmar |
10 percent owner |
C/O 5AM VENTURES, 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107 |
| 5am Ventures Vi, L.p. |
10 percent owner |
501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107 |
Enliven Therapeutics (Enliven Therapeutics) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ELVN has been successfully added to your